<DOC>
	<DOCNO>NCT00869856</DOCNO>
	<brief_summary>This open-label , single-arm , baseline-controlled , multicenter efficacy safety switch study involve 500 CKD subject suffer anemia treat previously stable dose ESA s.c . Correction anemia maintain s.c. administration HX575 two frequency ( i.e . qw q2w ) , order maintain Hb target range 10.0-12.0 g/dL .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety Immunogenicity Subcutaneous HX575 Treatment Anemia Associated With Chronic Kidney Disease ( SWEEP )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female CKD subject without dialysis treatment Age &gt; 18 year Subjects document stable maintenance therapy ESA , s.c. least per week accordance relevant SmPC , least 3 month total weekly dose ≤ 300 IU/kg/week Subjects control symptomatic anemia , define mean Hb level 10.0 g/dL 12.0 g/dL , base four Hb measurement fourweek baseline period Adequate iron status , serum ferritin ≥ 100 µg/L transferrin saturation ≥ 20 % Confirmed negative antiEPO antibody assay sample take screen visit 4 Systemic cyclosporine History PRCA aplastic anemia History antiEPO antibody Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Treatment associate CRI</keyword>
</DOC>